C
ClarVista Medical
Modular intraocular lens system for cataract surgery
About ClarVista Medical
ClarVista Medical, Inc. was a clinical-stage ophthalmic device company that developed the HARMONI Modular Intraocular Lens (IOL) System, designed to restore vision following cataract surgery. The company was founded in 2012. Paul McLean served as the President and CEO.
The company's core product, the HARMONI Modular IOL System, is a two-component device featuring a stable base and an exchangeable optic. This modular design allows surgeons to better position the lens initially and to easily exchange the optic component post-surgery if necessary, without disturbing the capsular bag. The system was developed to address the unpredictability of refractive outcomes in traditional cataract surgery and to offer more control to surgeons. The components are made from a hydrophobic acrylic polymer and can be implanted through a small 2.2- to 2.4-mm corneal incision. The flexibility of the HARMONI system allows for the use of various optic types, including monofocal, toric, and multifocal, enabling a personalized approach to patient vision correction. Early studies indicated a significant reduction in the risk of posterior capsule opacification (PCO), a common complication after cataract surgery.
ClarVista Medical secured $14 million in a Series B financing round in May 2015, co-led by Cycad Group and Windham Venture Partners, with participation from existing investor New Enterprise Associates. The HARMONI system received its CE Mark in Europe in 2015. On September 20, 2017, Alcon acquired ClarVista Medical. The deal was valued at approximately $125-130 million, consisting of an initial cash payment and contingent considerations based on development and commercialization milestones.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 58.7/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Ophthalmology, medical implants, Surgery, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- B2C
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | May 2015 | $15M | $58M | Windham Venture Partners · Cycad Group · NEA | — |
| SERIES A✓Equity / VC | Jan 2012 | — | — | NEA | — |
Growth signals
Latest recorded traffic for ClarVista Medical is 0 monthly website visits. ClarVista Medical's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
ClarVista Medical in the Aliso Viejo ecosystem
The ClarVista Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
NEA
Windham Venture Partners- CGCycad Group
Other known investors1 additional known investor
Vensana Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about ClarVista Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ClarVista Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.




